FDA Grants Priority Review to Merck’s Keytruda Combo for Endometrial Carcinoma

Merck seeks approval for Keytruda (pembrolizumab) plus chemotherapy with carboplatin and paclitaxel for patients with primary advanced or recurrent endometrial carcinoma, alongside chemotherapy (carboplatin and paclitaxel).

Source link
#FDA #Grants #Priority #Review #Mercks #Keytruda #Combo #Endometrial #Carcinoma